Daxor Expands To Three New Facilities As Blood Volume Analysis Technology Gains Momentum Nationwide
Daxor Expands To Three New Facilities As Blood Volume Analysis Technology Gains Momentum Nationwide
Daxor's ezBVA Lab Service Spearheads Growth and Broader Market Adoption
Daxor的ezBVA实验室服务带头推动增长和更广泛的市场采纳
Oak Ridge, TN, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces the expansion of blood volume analysis (BVA) in three new facilities. Daxor's ezBVA lab service is a state-of-the-art CLIA certified facility that provides on-demand, next day blood volume analysis results. The company anticipates sustained accelerated sales growth during the rest of the year.
田纳西州奥克岭,2024年8月5日(全球新闻社) - Daxor公司 全球血容量测量技术领导者纳斯达克股票代码为DXR的Daxor宣布扩大三个新设施的血容量分析(BVA)。Daxor的ezBVA实验室服务是一家先进的CLIA认证实验室,可提供按需、次日的血容量分析结果。该公司预计在今年剩余时间内将维持加速的销售增长。
Recent sales wins include:
最近的销售利润包括:
- Leading full-service medical center in Georgia adopts Daxor's ezBVA Lab service.
- Second hospital, part of the largest non-profit health system in North Carolina, purchases a blood volume analyzer.
- Top-rated Central Florida hospital implements Daxor's ezBVA Lab service.
- 佐治亚州领先的全方位医疗中心采用Daxor的ezBVA实验室服务。
- 北卡罗来纳州最大的非营利性健康系统下属的第二家医院购买了血容量分析仪。
- 位于佛罗里达州中心评价最高的医院采用Daxor的ezBVA实验室服务。
"Providing efficient and effective options to implement our diagnostic solution empowers healthcare facilities to meet the dual challenges of enhancing patient care and managing expenses," said Jean Oertel, Sr. VP Commercialization and Customer Experience. "The increase in adoption of our blood volume analysis technology underscores its critical impact in advancing treatment effectiveness for fluid management and is driving further sales growth for the company."
Jean Oertel,高级副总裁商业化和客户体验表示:“提供高效、有效的选项来实施我们的诊断方案,使医疗保健设施能够应对加强患者护理和管理费用的双重挑战。我们的血容量分析技术的采用增加,突显了它在推进液体管理的治疗效果方面的关键影响,并为公司带来进一步的销售增长。”
About Daxor Corporation
Daxor Corporation (Nasdaq: DXR), is the global leader in blood volume measurement technology focused on blood volume testing innovation. We developed and market the BVA-100 (Blood Volume Analyzer), the only diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. Over 65,000+ tests have been performed at leading hospital centers across the U.S., enhancing hospital performance metrics in a broad range of surgical and medical conditions, including significantly reducing mortality and readmissions in heart failure and critical care. Daxor has several ongoing trials in the areas of heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the U.S. Department of Defense. Daxor's mission is to advance healthcare by enabling optimal fluid management with blood volume analysis. Daxor's vision is optimal blood volume for all. For more information, please visit our website at Daxor.com. Sign up to receive news on Daxor's innovative technology HERE.
关于Daxor公司
Daxor Corporation(纳斯达克股票代码为DXR)是全球血容量测量技术领域的领导者,专注于血容量测试创新。我们开发并销售BVA-100(血容量分析仪),这是唯一获得FDA批准的诊断性血液测试,可提供与患者特定规范相比的安全、准确、客观的血容量状态和组成的量化。在美国领先的医院中心已经进行了65000多项测试,在广泛的外科和医学病症中提高了医院的性能指标,包括在心力衰竭和重症护理中显著降低死亡率和再入院率。Daxor在心力衰竭治疗方面有几项正在进行的试验,并在与美国国家卫生研究院(NIH)的支持下开展一项合同开发分析仪,以改善作战伤员护理。Daxor的使命是通过血容量分析使流体管理达到最佳状态。Daxor的愿景是为所有人提供最佳的血容量。有关更多信息,请访问我们的网站。 Daxor.com。注册以接收关于Daxor的创新技术的新闻这里.
Forward-Looking Statements
Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
前瞻性声明
本新闻稿中的某些声明可能包括1995年《私人证券诉讼改革法》中的前瞻性声明,包括但不限于有关雇用销售人员和扩大我们分销渠道的影响的声明。前瞻性声明是基于当前期望和假设的未来事件的预测、投射和其他声明,因此受到风险和不确定性的影响。许多因素可能导致本新闻稿中前瞻性声明的实际未来事件与所述的前瞻性声明不同,包括但不限于与我们的后市临床数据收集活动相关的风险、我们的产品对患者的益处、我们对产品开发和商业化努力的期望、我们的产品市场和医生接受度的提高、潜在的竞争产品提供、知识产权保护、FDA监管行动、我们整合已收购的业务的能力,我们的期望关于与收购企业预期的协同效应和好处,以及我们在SEC提交的文件中描述的其他风险和不确定性。前瞻性声明仅适用于其作为之日的情况。Daxor并不承担公开更新或修订任何前瞻性声明的任何义务,无论是因为新信息、未来事件还是其他原因。
Investor Relations Contact:
Bret Shapiro
Sr. Managing Partner, CORE IR
1-516-222-2560
brets@coreir.com
投资者关系联系人:
Bret Shapiro
高级合伙人,CORE IR Bret Shapiro
1-516-222-2560
brets@coreir.com